Surrozen is a clinical-stage biotechnology company developing antibody therapeutics that modulate the Wnt signaling pathway to promote tissue repair and regeneration.
2 listed classes/securities ($SRZN, $SRZNW) are filed under this issuer; the holder table aggregates all of them.
| Ticker | Title of class | CUSIP | Sector | Filers | Value |
|---|---|---|---|---|---|
| $SRZN NASDAQ | COM NEW | 86889P208 | health | 2 | $20,694,580 |
| $SRZNW | *W EXP 08/01/203 | 86889P117 | — | 1 | $1,400 |
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Steve Cohen / Point72 | 75 | New buy | 664,272 | $17,237,858 | 0.0% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA (auto-surfaced) | 39 | Trimmed -50% | 133,207 | $3,456,722 | 0.1% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA (auto-surfaced) | 39 | Trimmed -50% | 83,333 | $1,400 | 0.0% |
| Filed | Insider | Role | Shares | Value | |
|---|---|---|---|---|---|
| 2026-03-25 | TCG Crossover Fund II, L.P. (cluster of 5) | 10%-owner | 121,881 | $3,012,439 | Form 4 |
| 2026-03-16 | TCG Crossover Fund II, L.P. (cluster of 5) | 10%-owner | 48,997 | $1,220,537 | Form 4 |
| 2026-02-13 | TCG Crossover Fund II, L.P. (cluster of 5) | 10%-owner | 18,856 | $444,931 | Form 4 |
| 2026-01-20 | Column Group Opportunity III GP, LP (cluster of 5) | 10%-owner | 32,507 | $641,611 | Form 4 |
| 2026-01-20 | Kutzkey Tim (cluster of 5) | director+10%-owner | 32,507 | $641,611 | Form 4 |
| 2026-01-15 | Kutzkey Tim (cluster of 5) | director+10%-owner | 17,993 | $357,311 | Form 4 |
| 2026-01-15 | TCG Opportunity III GP, LLC (cluster of 5) | 10%-owner | 17,993 | $357,311 | Form 4 |
| 2026-01-08 | Kutzkey Tim (cluster of 5) | director+10%-owner | 15,100 | $300,339 | Form 4 |
| 2026-01-08 | COLUMN GROUP III GP, LP (cluster of 5) | 10%-owner | 15,100 | $300,339 | Form 4 |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-10-17.